Gratus Capital LLC trimmed its position in Stryker Co. (NYSE:SYK) by 3.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,191 shares of the medical technology company’s stock after selling 730 shares during the quarter. Gratus Capital LLC’s holdings in Stryker were worth $3,088,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Lido Advisors LLC purchased a new stake in shares of Stryker in the first quarter worth approximately $356,000. Chicago Capital LLC purchased a new stake in shares of Stryker in the first quarter worth approximately $290,000. IFP Advisors Inc lifted its position in shares of Stryker by 6.5% in the first quarter. IFP Advisors Inc now owns 7,688 shares of the medical technology company’s stock worth $1,237,000 after purchasing an additional 472 shares in the last quarter. BTC Capital Management Inc. lifted its position in shares of Stryker by 8.7% in the first quarter. BTC Capital Management Inc. now owns 6,519 shares of the medical technology company’s stock worth $1,048,000 after purchasing an additional 522 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its position in shares of Stryker by 1.9% in the first quarter. Candriam Luxembourg S.C.A. now owns 62,945 shares of the medical technology company’s stock worth $10,130,000 after purchasing an additional 1,149 shares in the last quarter. Institutional investors own 74.93% of the company’s stock.
In other news, insider David Floyd sold 55,119 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $166.58, for a total value of $9,181,723.02. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Glenn S. Boehnlein sold 750 shares of the firm’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $160.00, for a total transaction of $120,000.00. Following the completion of the sale, the chief financial officer now owns 3,535 shares in the company, valued at approximately $565,600. The disclosure for this sale can be found here. In the last 90 days, insiders sold 134,200 shares of company stock worth $22,151,180. 7.30% of the stock is currently owned by corporate insiders.
Shares of Stryker opened at $172.90 on Wednesday, according to Marketbeat.com. The company has a market cap of $64.93 billion, a P/E ratio of 26.64, a price-to-earnings-growth ratio of 2.46 and a beta of 0.70. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.08 and a current ratio of 1.64. Stryker Co. has a twelve month low of $137.70 and a twelve month high of $174.44.
Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 26th. The medical technology company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.08. Stryker had a net margin of 8.00% and a return on equity of 25.65%. The firm had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.20 billion. During the same quarter last year, the firm earned $1.48 earnings per share. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. analysts predict that Stryker Co. will post 7.23 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 31st. Stockholders of record on Friday, June 29th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Thursday, June 28th. This represents a $1.88 annualized dividend and a dividend yield of 1.09%. Stryker’s payout ratio is 28.97%.
A number of research firms have recently issued reports on SYK. Zacks Investment Research raised shares of Stryker from a “hold” rating to a “buy” rating and set a $192.00 price target for the company in a research report on Monday. Citigroup increased their price target on shares of Stryker from $166.00 to $171.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 1st. SunTrust Banks reissued a “buy” rating and issued a $179.00 price target (up from $161.00) on shares of Stryker in a research report on Friday, January 26th. Stifel Nicolaus increased their price target on shares of Stryker from $183.00 to $187.00 and gave the stock a “buy” rating in a research report on Friday, April 27th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Stryker in a research report on Friday, April 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the company. Stryker presently has a consensus rating of “Buy” and an average price target of $171.40.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.